Author: Genes2Me

Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry’s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics—delivering integrated solutions that advance precision medicine and improve lives worldwide.

Personalized genetic test, predictive test, genetic test for fitness, genetic test for health, genes2fit, genes2health, pharmacogenomics test

Genetic TestingFebruary 20, 2020May 14, 2026

Know Your Future Health Risk through Genetic Test

G2M, with present challenges in the Diagnostics industry, opened a new dimension to overcome the issues through Predictive genetic testing. Through genetic testing for health,…

Clinical exome, human genome, exome sequencing, whole genome sequencing, genetic testing, genetic disorders

Exome SequencingJanuary 17, 2020May 14, 2026

What is Clinical Exome Sequencing?

The Human Genome consists of around 3 billion nucleotides of DNA. Out of which only 1.5% of those nucleotides get translated into proteins. The exome…